Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ALT

Altimmune Inc

Mar 19 • 04:00PM ET

5.81

Dollar change +0.20
Percentage change 3.57	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: VTI IWM XBI VXF IBB VTWO IWO IWN VHT PTH

Index	RUT	P/E	-	EPS (ttm)	-1.34	Insider Own	1.04%	Shs Outstand	77.01M	Perf Week	4.68%
Market Cap	447.45M	Forward P/E	-	EPS next Y	-1.71	Insider Trans	1.39%	Shs Float	76.21M	Perf Month	-10.34%
Income	-95.06M	PEG	-	EPS next Q	-0.38	Inst Own	53.08%	Short Float	28.43%	Perf Quarter	-35.66%
Sales	0.02M	P/S	22372.64	EPS this Y	-10.71%	Inst Trans	2.46%	Short Ratio	8.26	Perf Half Y	-23.35%
Book/sh	1.71	P/B	3.40	EPS next Y	-15.09%	ROA	-54.33%	Short Interest	21.67M	Perf Year	-41.08%
Cash/sh	1.71	P/C	3.39	EPS next 5Y	-2.63%	ROE	-59.86%	52W Range	5.14 - 11.16	Perf YTD	-19.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.48%	ROI	-76.10%	52W High	-47.94%	Beta	0.84
Dividend TTM	-	Quick Ratio	13.10	Sales past 5Y	104.92%	Gross Margin	-1090.00%	52W Low	13.04%	ATR (14)	0.45
Dividend Ex-Date	Jan 20, 2017	Current Ratio	13.10	EPS Y/Y TTM	18.58%	Oper. Margin	-515860.00%	RSI (14)	46.68	Volatility	9.20% 7.76%
Employees	59	Debt/Eq	0.01	Sales Y/Y TTM	-95.31%	Profit Margin	-475295.00%	Recom	1.36	Target Price	22.38
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	39.92%	Payout	-	Rel Volume	0.66	Prev Close	5.61
Sales Surprise	-	EPS Surprise	0.75%	Sales Q/Q	-86.49%	Earnings	Feb 27 BMO	Avg Volume	2.62M	Price	5.81
SMA20	-1.27%	SMA50	-9.41%	SMA200	-16.42%	Trades		Volume	1,733,473	Change	3.57%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Today 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
07:30AM	Loading…
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
07:00AM	Loading…
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
07:30AM	Loading…
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
Jun-22-24 04:45PM	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions (GlobeNewswire)
Jun-21-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) +7.91%
Jun-20-24 07:30AM	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways (GlobeNewswire)
Jun-18-24 07:30AM	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
Jun-05-24 07:00AM	Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 07:31AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024 (GlobeNewswire)
May-27-24 02:56PM	The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop (InvestorPlace)
May-23-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) -6.34%
May-21-24 02:53PM	Altimmune, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALT (GlobeNewswire)
09:00AM	Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) (PR Newswire)
May-20-24 03:01PM	Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights (Business Wire)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace) -10.00%
May-15-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire) +13.43%
May-14-24 12:47PM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights ALT (GlobeNewswire) +6.11%
May-10-24 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 03:07PM	Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report (InvestorPlace) -18.65%
Jan-02-24 07:30AM	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 (GlobeNewswire) -6.49%
Dec-01-23 11:45AM	Why Is Altimmune (ALT) Stock Up 43% Today? (InvestorPlace) +12.97%
04:47AM	Altimmune, seeking edge on Lilly and Novo, puts heart health at center of phase 2 obesity data drop (FierceBiotech.com)
Nov-30-23 04:24PM	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide (GlobeNewswire)
Nov-08-23 09:15AM	Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:00AM	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-31-23 07:30AM	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (GlobeNewswire)
Oct-26-23 07:30AM	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Oct-25-23 07:30AM	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-17-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-12-23 07:30AM	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +7.41%
Aug-30-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +6.96%
Jun-16-23 07:30AM	Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023 (GlobeNewswire)
May-31-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-11-23 07:00AM	Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +7.03%
May-08-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Feb 01 '25	Option Exercise	0.00	16,545	0	351,645	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Jan 30 '25	Option Exercise	0.00	26,775	0	342,696	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	78,898	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	74,000	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	69,562	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	62,921	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	57,910	Jan 28 09:06 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	36,150	Jan 28 09:05 PM
Harris Matthew Scott	Chief Medical Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	69,719	Jan 28 09:05 PM
Garg Vipin K	President and CEO	Jan 25 '25	Option Exercise	0.00	42,050	0	334,078	Jan 28 09:04 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '25	Option Exercise	0.00	9,375	0	24,035	Jan 03 04:40 PM
Drutz David	Director	Aug 19 '24	Option Exercise	2.55	41,750	106,375	63,708	Aug 20 06:05 PM
Drutz David	Director	Aug 19 '24	Sale	6.90	16,011	110,547	41,958	Aug 20 06:05 PM

Open in Screener

ATOS

Atossa Therapeutics Inc

Mar 19 • 04:00PM ET

0.7433

Dollar change +0.0184
Percentage change 2.54	%

Healthcare • Biotechnology • USA • NASD

ATOS Atossa Therapeutics Inc daily Stock Chart

Peers: MRNA SRPT BNTX CYTK AXSM NVAX KPTI ADAP RGLS

| Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-0.21	Insider Own	0.02%	Shs Outstand	125.80M	Perf Week	3.71%
Market Cap	93.50M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	125.78M	Perf Month	-11.29%
Income	-26.91M	PEG	-	EPS next Q	-0.06	Inst Own	28.40%	Short Float	7.05%	Perf Quarter	-33.63%
Sales	0.00M	P/S	-	EPS this Y	9.72%	Inst Trans	1.38%	Short Ratio	12.73	Perf Half Y	-50.77%
Book/sh	0.59	P/B	1.26	EPS next Y	-24.62%	ROA	-29.71%	Short Interest	8.86M	Perf Year	-42.38%
Cash/sh	0.60	P/C	1.25	EPS next 5Y	-8.91%	ROE	-31.30%	52W Range	0.66 - 2.31	Perf YTD	-21.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.61%	ROI	-36.52%	52W High	-67.82%	Beta	1.43
Dividend TTM	-	Quick Ratio	13.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.62%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	13.30	EPS Y/Y TTM	9.11%	Oper. Margin	-	RSI (14)	44.96	Volatility	7.51% 6.35%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-16.16%	Payout	-	Rel Volume	0.53	Prev Close	0.72
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	696.19K	Price	0.74
SMA20	-0.63%	SMA50	-9.10%	SMA200	-37.06%	Trades		Volume	366,012	Change	2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-18	Initiated	Maxim Group	Buy	$2

Mar-11-25 08:15AM	Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications (GlobeNewswire)
Feb-05-25 08:00AM	Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care (GlobeNewswire)
Jan-30-25 08:17AM	Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 (GlobeNewswire)
Jan-23-25 08:15AM	Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 (GlobeNewswire)
Jan-06-25 09:00AM	Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer (GlobeNewswire)
09:40AM	Loading…
Dec-20-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-13-24 08:20AM	Atossa Therapeutics to present poster on Z-endoxifen at SABCS (TipRanks)
Dec-12-24 08:15AM	Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-11-24 08:15AM	Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (GlobeNewswire)
Dec-10-24 09:05AM	Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 08:15AM	Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-21-24 08:30AM	Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-20-24 08:30AM	Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.25%
Nov-12-24 08:30AM	Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.41%
Nov-05-24 08:30AM	Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development (GlobeNewswire)
06:30AM	Loading…
Nov-04-24 06:30AM	Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (GlobeNewswire)
Oct-31-24 08:15AM	Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer (GlobeNewswire)
Oct-28-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
Oct-21-24 08:30AM	Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer (GlobeNewswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire)
Oct-14-24 05:08PM	Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-01-24 08:30AM	Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum (GlobeNewswire)
Sep-19-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-10-24 08:30AM	Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer (GlobeNewswire) +7.35%
Sep-03-24 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-30-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice (Zacks)
Aug-28-24 08:30AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Aug-21-24 11:30AM	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer (GlobeNewswire)
Aug-20-24 08:30AM	Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations (GlobeNewswire)
08:30AM	Loading…
Aug-12-24 08:30AM	Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.98%
Jul-22-24 08:30AM	Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire) +10.45%
Jul-11-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks) +6.67%
07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace)
Jul-03-24 09:45AM	3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 (InvestorPlace)
Jul-02-24 04:15PM	Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer (GlobeNewswire)
Jun-28-24 08:30AM	Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Jun-17-24 08:30AM	Atossa Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-06-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 08:30AM	Atossa to Present at the Sidoti Small-Cap Investor Conference (GlobeNewswire)
May-28-24 08:30AM	Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model (GlobeNewswire)
May-20-24 12:00PM	Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy? (Zacks)
06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-15-24 08:30AM	Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
May-13-24 02:52PM	ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:50AM	Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines (GlobeNewswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
08:30AM	Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen (GlobeNewswire)
Apr-15-24 08:30AM	Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Apr-11-24 10:10AM	Atossa (ATOS) Reports Positive Results From EVANGELINE Study (Zacks)
08:30AM	Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference (GlobeNewswire)
Apr-09-24 11:59AM	Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen (GlobeNewswire) +5.14%
Apr-01-24 10:53PM	ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.11% -8.00%
04:00PM	Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient (GlobeNewswire) +20.16%
Mar-18-24 08:30AM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire)
Mar-12-24 08:30AM	Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors (GlobeNewswire) +9.17%
Mar-06-24 08:30AM	Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +12.75%
Feb-22-24 08:30AM	Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study (GlobeNewswire)
Feb-07-24 08:30AM	Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial (GlobeNewswire) +5.84%
Jan-09-24 08:30AM	Atossa Therapeutics Issues Letter to Shareholders (GlobeNewswire)
Dec-18-23 09:00AM	Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus (PR Newswire)
Dec-08-23 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-04-23 08:30AM	Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director (GlobeNewswire)
Nov-20-23 08:30AM	Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire) +8.82%
Nov-13-23 09:00AM	Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-23 09:00AM	Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors (GlobeNewswire) -6.49%
Oct-30-23 01:00PM	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group (PR Newswire)
Oct-11-23 08:30AM	Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later (PR Newswire)
Sep-18-23 09:25AM	Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment (ACCESSWIRE)
08:30AM	Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Aug-23-23 08:00AM	Atossa Therapeutics backing Endoxifen in the fight against breast cancer (News Direct)
Aug-14-23 08:30AM	Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.29%
Aug-08-23 09:00AM	Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023 (GlobeNewswire)
Jul-20-23 09:15AM	Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada (GlobeNewswire) +6.54%
Jul-13-23 04:15PM	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements (GlobeNewswire) -10.37%
Jul-12-23 09:00AM	50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis (ACCESSWIRE) +6.30%
Jul-10-23 09:15AM	Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
Jul-06-23 09:28PM	3 Penny Stocks to Make Your Get Rich Dreams Come True (InvestorPlace)
09:15AM	Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer (GlobeNewswire)
Jun-28-23 01:03PM	Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial (News Direct) +22.51%
09:15AM	Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial (GlobeNewswire)
Jun-27-23 09:15AM	Atossa Therapeutics Announces $10M Stock Repurchase Program (GlobeNewswire) +8.50%
Jun-22-23 04:15PM	Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023 (GlobeNewswire)
Jun-21-23 01:48PM	Atossa Therapeutics announces further patent protection for Endoxifen (News Direct)
10:13AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Jun-14-23 09:15AM	Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC (GlobeNewswire)
Jun-12-23 09:15AM	Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire)
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
May-23-23 07:00AM	Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator (GlobeNewswire) +15.02%
May-15-23 09:10AM	Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-23 09:00AM	Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices (PR Newswire)
May-09-23 09:15AM	Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-27-23 09:15AM	Atossa Therapeutics to Participate in Tribe Publics Webinar Event Redefining Breast Cancer Prevention and Treatment (GlobeNewswire)
Mar-30-23 11:00AM	We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate (Simply Wall St.)

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Finn Jonathan	Director	Apr 10 '24	Buy	1.77	25,000	44,250	25,000	Apr 11 04:05 PM

ALT

Altimmune Inc

ATOS

Atossa Therapeutics Inc

Upgrade your FINVIZ experience